For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
Artificial intelligence is rapidly becoming embedded across the pharmaceutical value chain, from drug discovery and clinical trial optimization to manufacturing and commercialization. As the technolog...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
The world’s population is aging at an unprecedented pace, creating one of the most significant long term shifts in global healthcare demand. By the coming decades, older adults will represent an incre...
Takeaways: Kashiv BioSciences gets a key regulatory step for its XOLAIR (omalizumab) biosimilar, ADL-018. The market implication is a likely cost-reduction play in a high-value o...
Patient centricity has become one of the most widely used, and often overused, terms in the biopharma industry. In Canadian Health discussions, nearly every stakeholder references it in some form, emb...
Takeaways: This notice of allowance shores up Anixa’s IP moat around its AMHR2‑targeted ovarian cancer vaccine and aligns Canada with its existing US patent protection. ...
The healthcare and biopharma industries are facing a growing talent crisis that threatens to slow innovation and place additional strain on already burdened systems. Within Canadian Health, workforce ...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
The COVID-19 pandemic exposed critical vulnerabilities in global biopharma supply chains, disrupting the flow of raw materials, APIs, and finished therapies at an unprecedented scale. What was once op...
